Stock IBT B INFANT BACTERIAL THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Infant Bacterial Therapeutics AB

Equities

IBT B

SE0008015259

Pharmaceuticals

Delayed Nasdaq Stockholm
Other stock markets
 05:17:03 2024-04-29 am EDT 		5-day change 1st Jan Change
89.4 SEK +1.82% Intraday chart for Infant Bacterial Therapeutics AB +2.52% -0.67%
Feb. 08 Infant Bacterial Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 08 Infant Bacterial Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,589 1,605 1,257 749.9 561.3 1,212
Enterprise Value (EV) 1 1,046 1,110 833.9 363.2 225.5 883.4
P/E ratio -37.6 x -34.7 x -17.5 x -16.7 x -8.58 x -9.04 x
Yield - - - - - -
Capitalization / Revenue - - - - - 15,745,815,584 x
EV / Revenue - - - - - 11,472,257,143 x
EV / EBITDA - - - - - -
EV / FCF -34.8 x -36.3 x -17.8 x -18.2 x -7.87 x -13.7 x
FCF Yield -2.87% -2.76% -5.62% -5.5% -12.7% -7.29%
Price to Book 2.85 x 3.15 x 2.86 x 1.9 x 1.69 x 3.97 x
Nbr of stocks (in thousands) 11,226 11,226 11,226 11,226 11,226 13,471
Reference price 2 141.5 143.0 112.0 66.80 50.00 90.00
Announcement Date 3/1/19 4/3/20 4/9/21 3/31/22 3/22/23 3/25/24
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - 0.077
EBITDA - - - - - -
EBIT 1 -39.42 -47.2 -72.23 -44.67 -65.82 -134.6
Operating Margin - - - - - -174,827.27%
Earnings before Tax (EBT) 1 -40.61 -46.32 -72.01 -44.99 -65.45 -123.1
Net income 1 -40.61 -46.32 -72.01 -44.99 -65.45 -123.1
Net margin - - - - - -159,828.57%
EPS 2 -3.764 -4.126 -6.414 -4.008 -5.830 -9.953
Free Cash Flow 1 -30.03 -30.62 -46.84 -19.96 -28.66 -64.36
FCF margin - - - - - -83,585.23%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/1/19 4/3/20 4/9/21 3/31/22 3/22/23 3/25/24
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 542 495 423 387 336 329
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -30 -30.6 -46.8 -20 -28.7 -64.4
ROE (net income / shareholders' equity) -11.2% -8.68% -15.2% -10.8% -18% -38.6%
ROA (Net income/ Total Assets) -6.67% -5.45% -9.32% -6.5% -10.9% -24%
Assets 1 608.6 849.2 772.5 691.9 603.1 512.7
Book Value Per Share 2 49.60 45.50 39.20 35.20 29.50 22.70
Cash Flow per Share 2 48.30 44.10 37.70 34.50 29.90 24.40
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 3/1/19 4/3/20 4/9/21 3/31/22 3/22/23 3/25/24
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
INFANT BACTERIAL THERAPEUTICS AB Stock Infant Bacterial Therapeutics AB
-0.67% 108M
MERCK KGAA Stock Merck KGaA
+4.02% 70.44B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.97% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.83% 4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.48% 4.5B
YUHAN CORPORATION Stock Yuhan Corporation
+3.20% 3.85B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-21.36% 2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.67% 2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+8.38% 1.96B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+3.90% 1.65B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. IBT B Stock
  4. Financials Infant Bacterial Therapeutics AB